ストックスクリーナーアプリを入手
742.87
1.72%
-10.54
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Eli Lilly Teams With Laekna For Innovative Obesity Treatment - Finimize
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact with Chinese biotech for novel weight loss therapy - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is Novo Nordisk Stock a Buy Right Now? - The Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch
Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com
Lilly announces changes on board of directors - Yahoo Finance
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86% - Yahoo Finance
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance
Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com
Cramer's Lightning Round: Eli Lilly is a buy - NECN
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters
Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial - TipRanks
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose - Investors | Eli Lilly and Company
Eli Lilly follows J&J in suing Biden administration over 340B rebates - Healthcare Dive
Tesla, Eli Lilly lead market cap stock movers on Monday By Investing.com - Investing.com South Africa
Revisto, Inc announced that it has received $4 million in funding from LiveOak Ventures, Eli Lilly and Company, TAU VENTURES, Arkin Digital Health - Marketscreener.com
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure - Benzinga
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints - Marketscreener.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF - Clinical Trials Arena
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients (NYSE:LLY) - Seeking Alpha
Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Colorado Springs Gazette
Eli Lilly: positive results for tirzepatide - Marketscreener.com
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now - The Motley Fool
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? - Yahoo! Voices
Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity - Investors | Eli Lilly and Company
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping - Law360
Lilly Sues U.S. to Change Hospital Drug Discount Payments - The Wall Street Journal
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Lilly Sues HHS for Ending Planned 340B Drug Program Cash Rebates - Bloomberg Law
Eli Lilly sues to change hospital drug discount payments, WSJ reports - TipRanks
Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts - TipRanks
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program - Yahoo Finance
Eli Lilly: sues US federal agency - Marketscreener.com
Lilly sues US agency over blocking of drug-rebate program - Reuters
2.32%
0.15%
大文字化:
|
ボリューム (24 時間):